Skip to content

Bevacizumab conditional pharmacokinetics

Independent two-compartment total-bevacizumab PK with fixed allometry and drug accounting.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the two bevacizumab schedules change total exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

PK-only: Figure 3: 5 mg/kg every 2 weeks

Specified deterministic infusion and fixed-covariate history.

0–126 day

Scenario details

PK-only: Figure 3: 5 mg/kg every 2 weeks

Specified deterministic infusion and fixed-covariate history.

Readouts

Total bevacizumab · mg/L
Specified fixed-context quantity, unit coordinate or accounting readout.
AUC total · mg*day/L
Specified fixed-context quantity, unit coordinate or accounting readout.
Clearance · L/day
Specified fixed-context quantity, unit coordinate or accounting readout.
Accounted bevacizumab · mg
Specified fixed-context quantity, unit coordinate or accounting readout.

Study purpose

  • How do the model's key biological readouts change under pk-only: figure 3: 5 mg/kg every 2 weeks?

Assumptions

  • Deterministic fixed histories only; no original individual fitting, sampled populations or clinical dose selection.
  • Body weight and allometric coefficients stay fixed. Clearances scale with weight exponent0.75 and volumes with exponent1 relative to70kg.
  • Infusion durations are explicit chosen histories, not recovered individual infusion records.
  • All accounting and elapsed-time states are nonfeedback observers. AUC keeps physical mg*day/L under alternate hour display.
  • No claim of published figure-panel, population, residual-error or genotype-effect reconstruction.
  • The apparent peripheral pool contains total drug. This independent PK fit has no VEGF or binding state.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
126 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Independent two-compartment total-bevacizumab PK with fixed allometry and drug accounting.

Independent two-compartment total-bevacizumab PK with fixed allometry and drug accounting.

Model details

8 parameters · 5 states · 5 equations · 14 derived outputs

Classification & API access
Therapeutic
Bevacizumab
Modality
Monoclonal antibody
Target
VEGFA, VEGF165
Disease / scope
adult stage IV colorectal cancer
ParameterDefaultUnitDescription
Systemic clearanceCL_L_day0.17L/daySpecified reference clearance before fixed allometric scaling.
Intercompartmental clearanceQ_L_day0.36L/daySpecified bidirectional distribution clearance before allometric scaling.
Central distribution volumeV1_L3.14LSpecified apparent central volume before allometric scaling.
Peripheral distribution volumeV2_L2.63LSpecified apparent peripheral volume before allometric scaling.
Body weightbody_weight_kg70kgFixed throughout the selected infusion history.
Allometric reference weightreference_weight_kg70kg70kg normalization value.
Fixed clearance exponenttheta_cl_weight0.75—Allometric exponent on both CL and Q.
Fixed volume exponenttheta_v_weight1—Allometric exponent on both V1 and V2.

Related models

Bevacizumab and VEGF165 conditional QSS binding

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics